Inventor
CURRIE MARK G
US67 patents
⚠️ This page may combine multiple inventors who share the name “CURRIE MARK G”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
SEARLE & CO
12 patentsUS6046211AApr 4, 2000
Amidino derivatives useful as nitric oxide synthase inhibitors
SEARLE & CO35 citations96
US5707984AJan 13, 1998
Steroid nitrite/nitrate ester derivatives useful as anti-inflammatory drugs
SEARLE & CO87 citations96
US5969097AOct 19, 1999
Human guanylin
SEARLE & CO87 citations93
US5489670AFeb 6, 1996
Human uroguanylin
SEARLE & CO99 citations93
US5854234ADec 29, 1998
Amidino dervatives useful as nitric oxide synthase inhibitors
SEARLE & CO21 citations92
US5837698ANov 17, 1998
Steroid nitrite and nitrate ester derivatives useful as anti-inflammatory drugs
SEARLE & CO49 citations92
US5792758AAug 11, 1998
Steroid nitrite ester derivatives useful as anti-inflammatory drugs
SEARLE & CO19 citations92
US5674894AOct 7, 1997
Amidine derivatives useful as platelet aggregation inhibitors and vasodilators
SEARLE & CO19 citations84
US6071906AJun 6, 2000
Imidino piperidine derivatives useful as nitric oxide synthase inhibitors
SEARLE & CO4 citations74
US5985862ANov 16, 1999
Pharmaceutical compositions having steroid nitrate ester derivatives useful as anti-inflammatory drugs
SEARLE & CO14 citations73
US6448286B1Sep 10, 2002
Imino pyrrolidine derivatives useful as nitric oxide synthase inhibitors
SEARLE & CO2 citations63
US6653350B1Nov 25, 2003
Methods of treating osteoarthritis with inducible nitric oxide synthase inhibitors
SEARLE & CO3 citations57
IRONWOOD PHARMACEUTICALS INC
10 patentsUS7910546B2Mar 22, 2011
Methods and compositions for the treatment of gastrointestinal disorders
IRONWOOD PHARMACEUTICALS INC29 citations92
US7745409B2Jun 29, 2010
Methods and compositions for the treatment of gastrointestinal disorders
IRONWOOD PHARMACEUTICALS INC29 citations92
US7704947B2Apr 27, 2010
Methods and compositions for the treatment of gastrointestinal disorders
IRONWOOD PHARMACEUTICALS INC29 citations92
US9586937B2Mar 7, 2017
sGC stimulators
IRONWOOD PHARMACEUTICALS INC13 citations91
US9481689B2Nov 1, 2016
sGC stimulators
IRONWOOD PHARMACEUTICALS INC16 citations91
US7772188B2Aug 10, 2010
Methods and compositions for the treatment of gastrointestinal disorders
IRONWOOD PHARMACEUTICALS INC31 citations91
US7494979B2Feb 24, 2009
Method for treating congestive heart failure and other disorders
IRONWOOD PHARMACEUTICALS INC38 citations91
US10183021B2Jan 22, 2019
sGC stimulators
IRONWOOD PHARMACEUTICALS INC8 citations83
US9840536B2Dec 12, 2017
Methods and compositions for the treatment of gastrointestinal disorders
IRONWOOD PHARMACEUTICALS INC8 citations83
US8946158B2Feb 3, 2015
Treatments of gastrointestinal disorders
IRONWOOD PHARMACEUTICALS INC5 citations70
SEPRACOR INC
9 patentsUS7087785B2Aug 8, 2006
Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine and its formamide
SEPRACOR INC28 citations96
US7790772B2Sep 7, 2010
Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine
SEPRACOR INC15 citations92
US7589237B2Sep 15, 2009
Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine
SEPRACOR INC14 citations92
US7423179B2Sep 9, 2008
Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine
SEPRACOR INC12 citations92
US7253156B2Aug 7, 2007
Carbonate and carbamate modified forms of glucocorticoids in combination with B2 adrenergic agonists
SEPRACOR INC17 citations92
US7105699B2Sep 12, 2006
Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine and its formamide
SEPRACOR INC18 citations92
US7468362B2Dec 23, 2008
Carbonate and carbamate modified forms of glucocorticoids in combination with β2 adrenergic agonists
SEPRACOR INC3 citations62
US7018995B2Mar 28, 2006
Carbonate and carbamate modified forms of glucocorticoids
SEPRACOR INC4 citations62
US7034059B2Apr 25, 2006
Methods of using norfluoxetine
SEPRACOR INC4 citations57
CURRIE MARK G
5 patentsUS8110553B2Feb 7, 2012
Methods and compositions for the treatment of gastrointestinal disorders
CURRIE MARK G23 citations92
US8101579B2Jan 24, 2012
Methods and compositions for the treatment of gastrointestinal disorders
CURRIE MARK G22 citations91
US8507447B2Aug 13, 2013
Treatments for gastrointestinal disorders
CURRIE MARK G12 citations82
US9303066B2Apr 5, 2016
Treatments for gastrointestinal disorders
CURRIE MARK G3 citations71
US8735360B2May 27, 2014
Treatments for gastrointestinal disorders
CURRIE MARK G5 citations71
MICROBIA INC
4 patentsUS7371727B2May 13, 2008
Methods and compositions for the treatment of gastrointestinal disorders
MICROBIA INC60 citations97
US7304036B2Dec 4, 2007
Methods and compositions for the treatment of gastrointestinal disorders
MICROBIA INC77 citations97
US7205329B2Apr 17, 2007
Modulators of CRTH2 activity
MICROBIA INC117 citations95
US7320972B2Jan 22, 2008
4-Biarylyl-1-phenylazetidin-2-ones
MICROBIA INC24 citations88
CYCLERION THERAPEUTICS INC
4 patentsUS10639308B2May 5, 2020
sGC stimulators
CYCLERION THERAPEUTICS INC3 citations83
US10517874B2Dec 31, 2019
sGC stimulators
CYCLERION THERAPEUTICS INC4 citations83
US11207323B2Dec 28, 2021
sGC stimulators
CYCLERION THERAPEUTICS INC0 citations61
US11357777B2Jun 14, 2022
Use of sGC stimulators for the treatment of nonalcoholic steatohepatitis (NASH)
CYCLERION THERAPEUTICS INC0 citations60
SUNOVION PHARMACEUTICALS INC
2 patentsUS9072699B2Jul 7, 2015
Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine
SUNOVION PHARMACEUTICALS INC4 citations84
US8344030B2Jan 1, 2013
Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine
SUNOVION PHARMACEUTICALS INC3 citations73
MONSANTO CO
1 patentJERUSSI Thomas
1 patentPEARSON JAMES
1 patentTALLEY JOHN JEFFREY
1 patentShowing the top 50 of 67 patents by PatentIndex Score.